Inventor · disambiguated record
Sven Michel
Also filed as: MICHEL SVEN
4 granted patents·9 pending applications·0 citations·filing 2017–2024
56Inventor score
Files withSECARNA PHARMACEUTICALS GMBH & CO KG9LIPIGON PHARMACEUTICALS AB3THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV1
Top patents by PatentIndex Score
13 records- 0171US2024384272A1Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolismLIPIGON PHARMACEUTICALS AB·Filed 2024·Application pending·0 cites
- 0266US11781139B2ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolismLIPIGON PHARMACEUTICALS AB·Filed 2022·Granted Oct 10, 2023·0 cites·13 claims
- 0361US12024708B2ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolismLIPIGON PHARMACEUTICALS AB·Filed 2019·Granted Jul 2, 2024·0 cites·18 claims
- 0459US2025059547A1NLRP3 oligonucleotide for use in preventing and/or treating an inflammatory diseaseSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2022·Application pending·0 cites
- 0551US2024076673A1Oligonucleotides reducing the amount of CD73 mRNA and CD73 protein expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2021·Application pending·0 cites
- 0648US11781136B2Oligonucleotide inhibiting the expression of ChopSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2018·Granted Oct 10, 2023·0 cites·12 claims
- 0748US2023183708A1PD-1-specific antisense oligonucleotide and its use in therapySECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2021·Application pending·0 cites
- 0847US2022372482A1Modified antisense oligonucleotide for inhibition of FoxP3 expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 0946US2024067973A1Oligonucleotide for reducing the expression of angiotensin-converting enzyme 2 (ACE2) and its use for treating viral infectionTHE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV·Filed 2021·Application pending·0 cites
- 1041US2023067620A1Inhibitor of metadherin expressionSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 1139US2022220485A1PD-L1 antisense oligonucleotides for use in tumor treatmentSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2020·Application pending·0 cites
- 1237US10647987B2Approach for treating inflammatory disordersSECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2017·Granted May 12, 2020·0 cites·12 claims
- 1335US2019330640A1Oligonucleotides inhibiting the expression of nrp1SECARNA PHARMACEUTICALS GMBH & CO KG·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sven Michel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →